心臓マーカー検査市場:2027 年までの世界予測

出版:MarketsandMarkets(マーケッツアンドマーケッツ) 出版年月:2022年10月

心臓マーカー検査市場:製品 (試薬、機器)、コンポーネント (トロポニン I & T、CK-MB、ミオグロビン、BNP、hs-CRP)、疾患 (心筋梗塞、うっ血性心不全、アテローム性動脈硬化症)、エンドユーザー (ラボ、PoC、学界) – 2027 年までの世界予測
Cardiac Marker Testing Market by Product (Reagent, Instrument), Component (Troponin I & T, CK-MB, Myoglobin, BNP, hs-CRP), Disease (Myocardial Infarction, Congestive Heart Failure, Atheresclerosis), Enduser (Lab, PoC, Academia) – Global Forecast to 2027

ページ数 205
図表数 184
種別 英文調査報告書
価格

レポート目次    お問合せ・ご注文    価格・納期について

無料サンプル

MarketsandMarkets(マーケッツアンドマーケッツ)「心臓マーカー検査市場:製品 (試薬、機器)、コンポーネント (トロポニン I & T、CK-MB、ミオグロビン、BNP、hs-CRP)、疾患 (心筋梗塞、うっ血性心不全、アテローム性動脈硬化症)、エンドユーザー (ラボ、PoC、学界) – 2027 年までの世界予測 – Cardiac Marker Testing Market by Product (Reagent, Instrument), Component (Troponin I & T, CK-MB, Myoglobin, BNP, hs-CRP), Disease (Myocardial Infarction, Congestive Heart Failure, Atheresclerosis), Enduser (Lab, PoC, Academia) – Global Forecast to 2027」は世界の心臓マーカー検査市場を調査し、主要セグメント毎に行った分析・予測結果を提供します。

The global cardiac marker testing market is projected to reach USD 7.7 Billion by 2027 from USD 5.0 Billion in 2022, at a CAGR of 8.7% during the forecast period. The growth in the cardiac marker testing market is majorly driven by the significant rising cases of cardiovascular diseases, rapid growth in older population, and increasing research & funding initiatives from public/private organizations to discover novel cardiac biomarkers with improved efficacy for diagnosing heart conditions. According to the American Heart Association (AHA), the prevalence of CVD in the US is projected to reach 40.5% of the total population by 2030, from 36.9% in 2010.

However, technical problems associated with sample collection and storage and issues related to regulatory and reimbursement systems are some of the factors expected to restrain market growth to a certain extent.

Cardiac Marker Testing Market - MarketsandMarkets

“Troponin I and T estimated held the largest share of cardiac marker testing market in 2021, by Biomarker Type “

Based on biomarker type, the cardiac marker testing market is segmented into Troponin I and T, Creatine Kinase-MB (CK-MB), Natriuretic Peptide (BNP and Nt-proBNP), Myoglobin, High-sensitivity C-reactive Protein (hs-CRP), and other cardiac biomarkers. The Troponin I and T segment accounted for the largest share of 51.1 % of the cardiac marker testing market in 2021.
Factors such as high sensitivity and specificity, long elevation time (rises over 4-8 hours, peaks at 10-24 hours, and declines over ten days), and rapid prediction of outcomes are driving the growth of this segment. In addition, lab technicians are more familiar with the use of these markers as compared to other biomarkers

“Laboratory testing facilities segment accounted for the largest share of the cardiac marker testing market in 2021, by End user ”.
Based on end users, the cardiac marker testing market is segmented into laboratory testing facilities, academic institutes, and point-of-care testing facilities. In 2021, the laboratory testing facilities segment accounted for the largest share of 61.4% of the global cardiac marker testing market. Factors such as high testing throughput, better sensitivity & diagnostic accuracy compared to POC testing, and high preference for laboratory testing over POCT testing are driving the growth of this segment.

“The Asia Pacific market to grow at the highest CAGR during the forecast period”

The cardiac marker testing market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific is estimated to be the fastest-growing market for cardiac marker testing during the forecast period. The Asia Pacific market is driven due rising growing investments by government agencies in emerging countries of Asia Pacific for the improvement of healthcare infrastructure, growing number of independent clinical laboratories, presence of large patient population, and strategies adopted by players to increase their cardiac testing product reach in Asia Pacific.

Breakdown of supply-side primary interviews:
• By Company Type: Tier 1: 48%, Tier 2: 36%, and Tier 3: 16%
• By Designation: C-level: 10%, D-level: 14%, and Others: 76%
• By Region: North America: 40%, Europe: 32%, APAC: 20%, Latin America: 5%, and the Middle East & Africa: 3%

アジアの心臓マーカー検査市場 - マーケッツアンドマーケッツ

The major players operating in the cardiac marker testing market are F.Hoffmann-La Roche AG (Switzerland), Abbott Laboratories (US), Danaher Corporation (US), Siemens Healthineers AG (Germany), PerkinElmer, Inc. (US), bioMérieux SA (France), Becton, Dickinson and Company (US), Bio-Rad Laboratories, Inc. (US), Thermo Fisher Scientific Inc. (US), DiaSorin (Italy), and Tosoh Corporation (Japan), LSI Medience Corporation (Japan), Quidel Corporation (US), Randox Laboratories (UK), Guangzhou Wondfo Biotech Co., Ltd. (China), Boditech Med Inc. (South Korea), Tulip Diagnostics (P) Ltd (India), BTNX Inc. (Canada), Response Biomedical (Canada), Alfa Scientific Designs, Inc. (US), CTK Biotech, Inc. (US), Creative Diagnostics (US), LifeSign LLC. (US), CardioGenics Holdings Inc (Canada), and Atlas Medical GmbH (Germany).

Research Coverage

This report studies the cardiac marker testing market based on the product, biomarker type, disease, end user, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions).

Key Benefits of Buying the Report

This report focuses on various levels of analysis—industry trends, market share of top players, and company profiles, which together form basic views and analyze the competitive landscape, emerging segments of the cardiac marker testing market, and high-growth regions and their drivers, restraints, opportunities, and challenges. The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the market and garner greater market shares.


目次

1 INTRODUCTION 28
1.1 STUDY OBJECTIVES 28
1.2 MARKET DEFINITION 28
1.3 STUDY SCOPE 29
1.3.1 MARKETS COVERED 29
1.3.2 GEOGRAPHIC SCOPE 29
1.3.3 INCLUSIONS & EXCLUSIONS 30
1.3.4 YEARS CONSIDERED 30
1.4 CURRENCY CONSIDERED 30
1.5 LIMITATIONS 30
1.6 MARKET STAKEHOLDERS 31
1.7 SUMMARY OF CHANGES 31

2 RESEARCH METHODOLOGY 32
2.1 RESEARCH DATA 32
FIGURE 1 RESEARCH DESIGN 32
2.1.1 SECONDARY RESEARCH 33
2.1.2 PRIMARY RESEARCH 34
2.1.2.1 Key data from primary sources 34
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS:
SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 35
FIGURE 3 CARDIAC MARKER TESTING MARKET: BREAKDOWN OF PRIMARIES 35
2.2 MARKET SIZE ESTIMATION 35
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 36
2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION 36
2.2.2 MARKET ESTIMATION BASED ON END USERS 37
FIGURE 5 CARDIAC MARKER TESTING MARKET: MARKET SIZE ESTIMATION 37
2.2.3 PRIMARY RESEARCH VALIDATION 37
2.3 DATA TRIANGULATION 38
FIGURE 6 DATA TRIANGULATION METHODOLOGY 38
2.4 RESEARCH ASSUMPTIONS AND LIMITATIONS 39
2.4.1 RESEARCH ASSUMPTIONS 39
2.4.2 RESEARCH LIMITATIONS 39

3 EXECUTIVE SUMMARY 40
FIGURE 7 CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE,
2022 VS. 2027 (USD MILLION) 40
FIGURE 8 CARDIAC MARKER TESTING MARKET, BY END USER,
2022 VS. 2027 (USD MILLION) 41
FIGURE 9 GEOGRAPHICAL SNAPSHOT OF CARDIAC MARKER TESTING MARKET 42

4 PREMIUM INSIGHTS 43
4.1 CARDIAC MARKER TESTING MARKET OVERVIEW 43
FIGURE 10 RISING INCIDENCE OF CARDIOVASCULAR DISEASES AND ONGOING CLINICAL TRIALS FOR NOVEL BIOMARKERS TO DRIVE MARKET 43
4.2 CARDIAC MARKER TESTING MARKET SHARE, BY PRODUCT, 2022 VS. 2027 43
FIGURE 11 REAGENTS & KITS TO CONTINUE TO DOMINATE MARKET DURING FORECAST PERIOD 43
4.3 EUROPE: CARDIAC MARKER TESTING MARKET, BY END USER AND REGION 44
FIGURE 12 LABORATORY TESTING FACILITIES SEGMENT ACCOUNTED FOR LARGEST SHARE IN 2021 44
4.4 CARDIAC MARKER TESTING MARKET: GEOGRAPHICAL SNAPSHOT 44
FIGURE 13 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 44

5 MARKET OVERVIEW 45
5.1 INTRODUCTION 45
5.2 MARKET DYNAMICS 45
FIGURE 14 CARDIAC MARKER TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 45
5.2.1 DRIVERS 46
5.2.1.1 Rising incidence of cardiovascular diseases 46
5.2.1.2 Increasing geriatric population and subsequent rise in heart conditions worldwide 46
5.2.1.3 Growing research & funding initiatives from public & private organizations 47
5.2.1.4 Rising clinical studies for identification of novel cardiac biomarkers 47
5.2.2 RESTRAINTS 47
5.2.2.1 Technical issues related to sample collection & storage 47
5.2.2.2 Unfavorable regulatory processes and limited reimbursement structure 48
5.2.3 OPPORTUNITIES 48
5.2.3.1 Point-of-care testing with cardiac biomarkers 48
5.2.3.2 Ongoing research on novel cardiac biomarkers for cardiovascular diseases 49
5.2.3.3 Emerging markets offer high-growth opportunities 49
5.2.4 CHALLENGES 50
5.2.4.1 Challenges associated with biomarker assay validation 50
5.3 REGULATORY SCENARIO 50
TABLE 1 KEY REGULATORY BODIES & GOVERNMENT AGENCIES 50
5.3.1 KEY REGULATORY GUIDELINES 51
5.3.1.1 US 51
TABLE 2 US: CLASSIFICATION OF IN VITRO DIAGNOSTIC DEVICES 51
FIGURE 15 US: REGULATORY PROCESS FOR IVD DEVICES 52
5.3.1.2 Canada 53
FIGURE 16 CANADA: REGULATORY PROCESS FOR IVD DEVICES IN CANADA 53
5.3.1.3 Europe 53
TABLE 3 EUROPE: CLASSIFICATION OF IVD DEVICES 53
FIGURE 17 EUROPE: REGULATORY PROCESS FOR IVD DEVICES 54
5.3.1.4 Japan 55
FIGURE 18 REGULATORY PROCESS FOR IVD DEVICES IN JAPAN 55
TABLE 4 JAPAN: CLASSIFICATION OF IVD REAGENTS CLASSIFICATION OF IVD REAGENTS IN JAPAN 55
TABLE 5 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 56
5.3.1.5 China 56
TABLE 6 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 56
5.3.1.6 India 56
FIGURE 19 INDIA: REGULATORY PROCESS FOR IVD DEVICES 57
5.3.1.7 Russia 57
TABLE 7 RUSSIA: CLASSIFICATION OF IVD DEVICES 57
5.3.1.8 Mexico 58
FIGURE 20 MEXICO: REGULATORY PROCESS FOR IVD DEVICES 58
TABLE 8 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 58
5.3.1.9 Brazil 59
FIGURE 21 BRAZIL: REGULATORY PROCESS FOR IVD DEVICES 59
5.3.1.10 South Korea 59
TABLE 9 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 59
5.4 REIMBURSEMENT SCENARIO 60
TABLE 10 REIMBURSEMENT CODES FOR VARIOUS BIOMARKERS 60
5.5 VALUE CHAIN ANALYSIS 61
FIGURE 22 CARDIAC MARKER TESTING MARKET: VALUE CHAIN ANALYSIS 61
5.6 SUPPLY CHAIN ANALYSIS 62
FIGURE 23 DIRECT DISTRIBUTION—PREFERRED STRATEGY FOR PROMINENT COMPANIES 63
5.7 ECOSYSTEM ANALYSIS: PARENT MARKET (IN VITRO DIAGNOSTICS) 63
5.8 PRICING ANALYSIS 64
5.8.1 AVERAGE SELLING PRICE OF CARDIAC MARKET TEST KITS BY KEY PLAYERS 64
TABLE 11 CARDIAC BIOMARKER TROPONIN I AND T TEST KITS 64
TABLE 12 CARDIAC BIOMARKER CK-MB TEST KITS 64
TABLE 13 CARDIAC BIOMARKER BPN OR NT-PROBNP TEST KITS 64
TABLE 14 CARDIAC BIOMARKER MYOGLOBIN TEST KITS 64
TABLE 15 CARDIAC BIOMARKER C-REACTIVE PROTEIN (HS-CRP) TEST KITS 65
TABLE 16 AVERAGE SELLING PRICE OF CARDIAC MARKET TEST KITS TREND, BY COUNTRY (USD) 65
5.9 PORTER’S FIVE FORCES ANALYSIS 65
TABLE 17 CARDIAC MARKER TESTING MARKET: PORTER’S FIVE FORCES ANALYSIS 65
5.9.1 BARGAINING POWER OF BUYERS 66
5.9.2 BARGAINING POWER OF SUPPLIERS 66
5.9.3 THREAT OF NEW ENTRANTS 66
5.9.4 THREAT OF SUBSTITUTES 66
5.9.5 INTENSITY OF COMPETITIVE RIVALRY 66
5.10 PATENT ANALYSIS 67
FIGURE 24 TOP 10 PATENT APPLICANTS FOR CARDIAC MARKER TESTING (JANUARY 2012–SEPTEMBER 2022) 67
FIGURE 25 TOP 10 PATENT OWNERS FOR CARDIAC MARKER TESTING (JANUARY 2012–SEPTEMBER 2022) 67
5.11 KEY CONFERENCES & EVENTS (2022–2024) 68
TABLE 18 CARDIAC MARKER TESTING MARKET: DETAILED LIST OF MAJOR CONFERENCES & EVENTS 68
5.12 CASE STUDY 69
5.12.1 DEVELOPMENT OF HIGH-SENSITIVITY TROPONIN I 69
TABLE 19 CASE 1: DIAGNOSING LOWER LEVEL OF TROPONIN IN CARDIAC PATIENTS 69
5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 69
5.14 KEY STAKEHOLDERS & BUYING CRITERIA 70
5.14.1 KEY STAKEHOLDERS 70
FIGURE 26 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR CARDIAC MARKER TESTING KITS AND INSTRUMENTS 70
TABLE 20 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR PRODUCT SEGMENTS (%) 70
5.15 KEY BUYING CRITERIA BY END USERS 71

TABLE 21 KEY BUYING CRITERIA FOR PRODUCTS 71
6 CARDIAC MARKER TESTING MARKET, BY PRODUCT 72
6.1 INTRODUCTION 73
TABLE 22 CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 73
6.2 REAGENTS & KITS 73
6.2.1 RISING VOLUME OF DIAGNOSTIC TESTS TO DRIVE DEMAND 73
TABLE 23 CARDIAC MARKER TESTING MARKET FOR REAGENTS & KITS, BY REGION, 2020–2027 (USD MILLION) 74
TABLE 24 CARDIAC MARKER TESTING MARKET FOR REAGENTS & KITS, BY BIOMARKER TYPE, 2020–2027 (USD MILLION) 74
6.3 INSTRUMENTS 75
TABLE 25 CARDIAC MARKER TESTING MARKET FOR INSTRUMENTS, BY REGION, 2020–2027 (USD MILLION) 75
TABLE 26 CARDIAC MARKER TESTING MARKET FOR INSTRUMENTS, BY TECHNOLOGY, 2020–2027 (USD MILLION) 75
TABLE 27 CARDIAC MARKER TESTING MARKET FOR INSTRUMENTS, BY BIOMARKER TYPE, 2020–2027 (USD MILLION) 76
6.3.1 CHEMILUMINESCENCE 76
6.3.1.1 Most preferred method for quantification of cardiac biomarkers to drive segment growth 76
TABLE 28 CARDIAC MARKER TESTING MARKET FOR CHEMILUMINESCENCE, BY REGION, 2020–2027 (USD MILLION) 77
TABLE 29 CARDIAC MARKER TESTING MARKET FOR CHEMILUMINESCENCE, BY BIOMARKER TYPE, 2020–2027 (USD MILLION) 77
6.3.2 IMMUNOFLUORESCENCE 78
6.3.2.1 Demand for stable and safer reagents to support market growth 78
TABLE 30 CARDIAC MARKER TESTING MARKET FOR IMMUNOFLUORESCENCE, BY REGION, 2020–2027 (USD MILLION) 78
TABLE 31 CARDIAC MARKER TESTING MARKET FOR IMMUNOFLUORESCENCE, BY BIOMARKER TYPE, 2020–2027 (USD MILLION) 79
6.3.3 ELISA 79
6.3.3.1 Long shelf life and ease of use to propel segment growth 79
TABLE 32 CARDIAC MARKER TESTING MARKET FOR ELISA, BY REGION, 2020–2027 (USD MILLION) 79
TABLE 33 CARDIAC MARKER TESTING MARKET FOR ELISA, BY BIOMARKER TYPE, 2020–2027 (USD MILLION) 80
6.3.4 IMMUNOCHROMATOGRAPHY 80
6.3.4.1 Increasing use in point-of-care settings to drive adoption of this technique 80
TABLE 34 CARDIAC MARKER TESTING MARKET FOR IMMUNOCHROMATOGRAPHY, BY REGION, 2020–2027 (USD MILLION) 81
TABLE 35 CARDIAC MARKER TESTING MARKET FOR IMMUNOCHROMATOGRAPHY, BY BIOMARKER TYPE, 2020–2027 (USD MILLION) 81

7 CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE 82
7.1 INTRODUCTION 83
TABLE 36 CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2020–2027 (USD MILLION) 83
7.2 TROPONIN I AND T 83
7.2.1 HIGH SENSITIVITY AND SPECIFICITY IN DETECTION OF CVD TO DRIVE MARKET 83
TABLE 37 CHARACTERISTICS OF TROPONIN CARDIAC MARKERS 84
TABLE 38 CARDIAC MARKER TESTING MARKET FOR TROPONIN I AND T, BY REGION, 2020–2027 (USD MILLION) 84
TABLE 39 CARDIAC MARKER TESTING MARKET FOR TROPONIN I AND T, BY DISEASE, 2020–2027 (USD MILLION) 85
TABLE 40 CARDIAC MARKER TESTING MARKET FOR TROPONIN I AND T, BY END USER, 2020–2027 (USD MILLION) 85
7.3 CREATINE KINASE-MB (CK-MB) 85
7.3.1 DIAGNOSIS OF ACUTE MYOCARDIAL INJURY USING CK-MB TO DRIVE MARKET 85
TABLE 41 CHARACTERISTICS OF CK-MB CARDIAC MARKER 86
TABLE 42 CARDIAC MARKER TESTING MARKET FOR CREATINE KINASE-MB (CK-MB), BY REGION, 2020–2027 (USD MILLION) 86
TABLE 43 CARDIAC MARKER TESTING MARKET FOR CREATINE KINASE-MB (CK-MB), BY DISEASE, 2020–2027 (USD MILLION) 87
TABLE 44 CARDIAC MARKER TESTING MARKET FOR CREATINE KINASE-MB (CK-MB), BY END USER, 2020–2027 (USD MILLION) 87

7.4 NATRIURETIC PEPTIDE (BNP AND NT-PROBNP) 87
7.4.1 USE OF BNP WITH OTHER CARDIAC MARKERS TO ENHANCE UTILIZATION 87
TABLE 45 CARDIAC MARKER TESTING MARKET FOR NATRIURETIC PEPTIDE (BNP AND NT-PROBNP), BY REGION, 2020–2027 (USD MILLION) 88
TABLE 46 CARDIAC MARKER TESTING MARKET FOR NATRIURETIC PEPTIDE (BNP AND NT-PROBNP), BY DISEASE, 2020–2027 (USD MILLION) 88
TABLE 47 CARDIAC MARKER TESTING MARKET FOR NATRIURETIC PEPTIDE (BNP AND NT-PROBNP), BY END USER, 2020–2027 (USD MILLION) 89
7.5 MYOGLOBIN 89
7.5.1 RAPID INCREASE AND NORMALIZATION ASSOCIATED WITH MYOGLOBIN TO DRIVE MARKET 89
TABLE 48 CHARACTERISTICS OF MYOGLOBIN CARDIAC MARKERS 89
TABLE 49 CARDIAC MARKER TESTING MARKET FOR MYOGLOBIN, BY REGION, 2020–2027 (USD MILLION) 90
TABLE 50 CARDIAC MARKER TESTING MARKET FOR MYOGLOBIN, BY DISEASE, 2020–2027 (USD MILLION) 90
TABLE 51 CARDIAC MARKER TESTING MARKET FOR MYOGLOBIN, BY END USER, 2020–2027 (USD MILLION) 91
7.6 HIGH-SENSITIVITY C-REACTIVE PROTEIN (HSCRP) 91
7.6.1 ABILITY OF HSCRP TESTS TO ACCURATELY MEASURE LOW LEVELS OF CRP TO SUPPORT MARKET GROWTH 91
TABLE 52 CUT-OFFS FOR CRP USING STANDARDIZED ASSAYS 91
TABLE 53 CARDIAC MARKER TESTING MARKET FOR HIGH-SENSITIVITY C-REACTIVE PROTEIN (HSCRP), BY REGION, 2020–2027 (USD MILLION) 92
TABLE 54 CARDIAC MARKER TESTING MARKET FOR HIGH-SENSITIVITY C-REACTIVE PROTEIN (HSCRP), BY DISEASE, 2020–2027 (USD MILLION) 92
TABLE 55 CARDIAC MARKER TESTING MARKET FOR HIGH-SENSITIVITY C-REACTIVE PROTEIN (HSCRP), BY END USER, 2020–2027 (USD MILLION) 93
7.7 OTHER CARDIAC BIOMARKERS 93
TABLE 56 CARDIAC MARKER TESTING MARKET FOR OTHER CARDIAC BIOMARKERS, BY REGION, 2020–2027 (USD MILLION) 94
TABLE 57 CARDIAC MARKER TESTING MARKET FOR OTHER CARDIAC BIOMARKERS, BY DISEASE, 2020–2027 (USD MILLION) 94
TABLE 58 CARDIAC MARKER TESTING MARKET FOR OTHER CARDIAC BIOMARKERS, BY END USER, 2020–2027 (USD MILLION) 95
8 CARDIAC MARKER TESTING MARKET, BY DISEASE 96
8.1 INTRODUCTION 97
TABLE 59 CARDIAC MARKER TESTING MARKET, BY DISEASE, 2020–2027 (USD MILLION) 97
8.2 MYOCARDIAL INFARCTION 97
8.2.1 AVAILABILITY OF HIGH-SENSITIVITY BIOMARKERS FOR DETECTION OF MI TO DRIVE MARKET 97
TABLE 60 CARDIAC MARKER TESTING MARKET FOR MYOCARDIAL INFARCTION, BY REGION, 2020–2027 (USD MILLION) 98

8.3 CONGESTIVE HEART FAILURE 98
8.3.1 INCREASING USE OF MULTI-MARKER TESTING TO SUPPORT MARKET GROWTH 98
TABLE 61 CARDIAC MARKER TESTING MARKET FOR CONGESTIVE HEART FAILURE, BY REGION, 2020–2027 (USD MILLION) 99
8.4 ACUTE CORONARY SYNDROME 99
8.4.1 INCREASING INCIDENCE OF RISK FACTORS ASSOCIATED WITH ACS TO DRIVE ADOPTION OF CARDIAC MARKERS 99
TABLE 62 CARDIAC MARKER TESTING MARKET FOR ACUTE CORONARY SYNDROME, BY REGION, 2020–2027 (USD MILLION) 100
8.5 ATHEROSCLEROSIS 100
8.5.1 HIGH PREVALENCE OF ATHEROSCLEROSIS TO DRIVE UPTAKE OF CARDIAC MARKERS 100
TABLE 63 CARDIAC MARKER TESTING MARKET FOR ATHEROSCLEROSIS, BY REGION, 2020–2027 (USD MILLION) 101
8.6 ISCHEMIA 101
8.6.1 MULTIPLE COMPLICATIONS CAUSED BY ISCHEMIA TO DRIVE ADOPTION OF DIAGNOSTIC TESTS 101
TABLE 64 CARDIAC MARKER TESTING MARKET FOR ISCHEMIA, BY REGION, 2020–2027 (USD MILLION) 101
9 CARDIAC MARKER TESTING MARKET, BY END USER 102
9.1 INTRODUCTION 103
TABLE 65 CARDIAC MARKER TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 103
9.2 LABORATORY TESTING FACILITIES 103
TABLE 66 CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2020–2027 (USD MILLION) 104
TABLE 67 CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY REGION, 2020–2027 (USD MILLION) 104
9.2.1 HOSPITAL LABORATORIES 104
9.2.1.1 Emergency patient care and early diagnosis associated with in-house labs to drive market 104
TABLE 68 CARDIAC MARKER TESTING MARKET FOR HOSPITAL LABORATORIES, BY REGION, 2020–2027 (USD MILLION) 105
9.2.2 REFERENCE LABORATORIES 105
9.2.2.1 Affordable and time-efficient services associated with reference laboratories to support market growth 105
TABLE 69 CARDIAC MARKER TESTING MARKET FOR REFERENCE LABORATORIES, BY REGION, 2020–2027 (USD MILLION) 105
9.2.3 CONTRACT TESTING LABORATORIES 106
9.2.3.1 Ability to perform multiple tests and cover wider matrices to support market growth 106
TABLE 70 CARDIAC MARKER TESTING MARKET FOR CONTRACT TESTING LABORATORIES, BY REGION, 2020–2027 (USD MILLION) 106

9.3 ACADEMIC INSTITUTES 106
9.3.1 CONTINUOUS RESEARCH & DEVELOPMENT OF NOVEL BIOMARKERS TO DRIVE MARKET 106
TABLE 71 CARDIAC MARKER TESTING MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2020–2027 (USD MILLION) 107
9.4 POINT-OF-CARE TESTING FACILITIES 107
9.4.1 EARLY DETECTION AND LOWER TURNAROUND TIME TO DRIVE MARKET 107
TABLE 72 CARDIAC MARKER TESTING MARKET FOR POINT-OF-CARE TESTING FACILITIES, BY REGION, 2020–2027 (USD MILLION) 108

10 CARDIAC MARKER TESTING MARKET, BY REGION 109
10.1 INTRODUCTION 110
TABLE 73 CARDIAC MARKER TESTING MARKET, BY REGION, 2020–2027 (USD MILLION) 110
10.2 NORTH AMERICA 110
FIGURE 27 NORTH AMERICA: CARDIAC MARKER TESTING MARKET SNAPSHOT 111
TABLE 74 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 111
TABLE 75 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2020–2027 (USD MILLION) 112
TABLE 76 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 112
TABLE 77 NORTH AMERICA: CARDIAC MARKER TESTING INSTRUMENTS, BY TECHNOLOGY, 2020–2027 (USD MILLION) 113
TABLE 78 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 113
10.2.1 US 113
10.2.1.1 Growing support from NIH for development of novel cardiac biomarkers to drive market 113
TABLE 79 US: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 114
10.2.2 CANADA 114
10.2.2.1 Increasing government initiatives supporting cardiac marker testing to boost market growth 114
TABLE 80 CANADA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 115
10.3 EUROPE 115
TABLE 81 EUROPE: CARDIAC MARKER TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 115
TABLE 82 EUROPE CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2020–2027 (USD MILLION) 116
TABLE 83 EUROPE: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 116
TABLE 84 EUROPE: CARDIAC MARKER TESTING MARKET FOR INSTRUMENTS, BY TECHNOLOGY, 2020–2027 (USD MILLION) 116
TABLE 85 EUROPE: CARDIAC MARKER TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 117
10.3.1 GERMANY 117
10.3.1.1 Higher healthcare expenditure to drive demand for diagnostic tests 117
TABLE 86 GERMANY: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 117
10.3.2 UK 118
10.3.2.1 Government initiatives to expand diagnostic facilities to boost adoption of cardiac biomarkers 118
TABLE 87 UK: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 118
10.3.3 FRANCE 118
10.3.3.1 Rising demand for early CVD diagnosis to drive market 118
TABLE 88 FRANCE: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 119
10.3.4 ITALY 119
10.3.4.1 Adoption of advanced diagnostic technologies to drive market 119
TABLE 89 ITALY: CARDIAC MARKER TESTING MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 119
10.3.5 SPAIN 120
10.3.5.1 Establishment of large and advanced laboratories to drive uptake of cardiac marker testing 120
TABLE 90 SPAIN: CARDIAC MARKER TESTING MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 120
10.3.6 REST OF EUROPE (ROE) 120
TABLE 91 REST OF EUROPE: CARDIAC MARKER TESTING MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 121
10.4 ASIA PACIFIC 121
FIGURE 28 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET SNAPSHOT 122
TABLE 92 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 123
TABLE 93 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2020–2027 (USD MILLION) 123
TABLE 94 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 124
TABLE 95 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR INSTRUMENTS,
BY TECHNOLOGY, 2020–2027 (USD MILLION) 124
TABLE 96 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY END USER,
2020–2027 (USD MILLION) 124
10.4.1 JAPAN 125
10.4.1.1 Presence of established healthcare system with advanced laboratory facilities to drive market 125
TABLE 97 JAPAN: CARDIAC MARKER TESTING MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 125
10.4.2 CHINA 125
10.4.2.1 Increasing number of independent clinical laboratories to drive demand for cardiac markers 125
TABLE 98 CHINA: CARDIAC MARKER TESTING MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 126
10.4.3 INDIA 126
10.4.3.1 Presence of large patient population to drive demand for cardiac marker testing 126
TABLE 99 INDIA: CARDIAC MARKER TESTING MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 127
10.4.4 SOUTH KOREA 127
10.4.4.1 Growing number of private hospitals to drive adoption of advanced testing services 127
TABLE 100 SOUTH KOREA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 127
10.4.5 AUSTRALIA 128
10.4.5.1 High healthcare expenditure to support market growth 128
TABLE 101 AUSTRALIA: CARDIAC MARKER TESTING MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 128
10.4.6 REST OF ASIA PACIFIC (ROAPAC) 128
TABLE 102 REST OF ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 128
10.5 LATIN AMERICA 129
TABLE 103 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 129
TABLE 104 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2020–2027 (USD MILLION) 130
TABLE 105 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 130
TABLE 106 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR INSTRUMENTS,
BY TECHNOLOGY, 2020–2027 (USD MILLION) 130
TABLE 107 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY END USER,
2020–2027 (USD MILLION) 131
10.5.1 BRAZIL 131
10.5.1.1 Rising government support for advancements in healthcare to support market growth 131
TABLE 108 BRAZIL: CARDIAC MARKER TESTING MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 131
10.5.2 MEXICO 132
10.5.2.1 Rising demand for technologically advanced products to drive uptake for cardiac markers 132
TABLE 109 MEXICO: CARDIAC MARKER TESTING MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 132
10.5.3 REST OF LATIN AMERICA (ROLATAM) 132
TABLE 110 REST OF LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 133
10.6 MIDDLE EAST & AFRICA 133
10.6.1 RISING IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO DRIVE DEMAND FOR ADVANCED MARKERS 133
TABLE 111 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2020–2027 (USD MILLION) 133
TABLE 112 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 134
TABLE 113 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET FOR INSTRUMENTS, BY TECHNOLOGY, 2020–2027 (USD MILLION) 134
TABLE 114 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 134

11 COMPETITIVE LANDSCAPE 135
11.1 OVERVIEW 135
11.2 STRATEGIES ADOPTED BY KEY PLAYERS/RIGHT TO WIN 135
FIGURE 29 OVERVIEW OF STRATEGIES ADOPTED BY COMPANIES (2019−2022) 136
11.3 REVENUE ANALYSIS 137
FIGURE 30 REVENUE SHARE ANALYSIS OF TOP FIVE PLAYERS (2018−2021) 137
11.4 CARDIAC MARKER TESTING MARKET: MARKET SHARE ANALYSIS, BY KEY PLAYER (2021) 137
FIGURE 31 CARDIAC MARKER TESTING MARKET SHARE, BY KEY PLAYER (2021) 138
TABLE 115 CARDIAC MARKER TESTING MARKET: DEGREE OF COMPETITION 138
11.5 COMPANY EVALUATION QUADRANT FOR MAJOR PLAYERS (AS OF 2021) 139
11.5.1 STARS 139
11.5.2 EMERGING LEADERS 139
11.5.3 PERVASIVE PLAYERS 139
11.5.4 PARTICIPANTS 140
FIGURE 32 CARDIAC MARKER TESTING MARKET:
COMPANY EVALUATION QUADRANT (2021) 140
11.6 COMPANY EVALUATION QUADRANT (SMES/STARTUPS) 141
11.6.1 PROGRESSIVE COMPANIES 141
11.6.2 RESPONSIVE COMPANIES 141
11.6.3 DYNAMIC COMPANIES 141
11.6.4 STARTING BLOCKS 141
FIGURE 33 CARDIAC MARKER TESTING MARKET:
COMPETITIVE LEADERSHIP MAPPING (SMES/STARTUPS) 142
11.7 COMPETITIVE BENCHMARKING 143
TABLE 116 OVERALL FOOTPRINT ANALYSIS 143
TABLE 117 PRODUCT FOOTPRINT ANALYSIS 144
TABLE 118 REGIONAL FOOTPRINT ANALYSIS 145
11.8 COMPETITIVE SCENARIO (2019–2022) 146
11.8.1 PRODUCT LAUNCHES & APPROVALS 146
11.8.2 DEALS 147
11.8.3 OTHER DEVELOPMENTS 147

12 COMPANY PROFILES 148
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1 KEY PLAYERS 148
12.1.1 F. HOFFMANN-LA ROCHE AG 148
TABLE 119 F. HOFFMANN-LA ROCHE AG: BUSINESS OVERVIEW 148
FIGURE 34 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2021) 149
12.1.2 ABBOTT LABORATORIES 152
TABLE 120 ABBOTT LABORATORIES: BUSINESS OVERVIEW 152
FIGURE 35 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021) 153
12.1.3 SIEMENS HEALTHINEERS AG 156
TABLE 121 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW 156
FIGURE 36 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2021) 157
12.1.4 DANAHER CORPORATION 160
TABLE 122 DANAHER CORPORATION: BUSINESS OVERVIEW 160
FIGURE 37 DANAHER CORPORATION: COMPANY SNAPSHOT (2021) 161
12.1.5 BIOMÉRIEUX SA 163
TABLE 123 BIOMÉRIEUX SA: BUSINESS OVERVIEW 163
FIGURE 38 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2021) 164
12.1.6 BECTON, DICKINSON AND COMPANY (BD) 165
TABLE 124 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW 165
FIGURE 39 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2021) 166
12.1.7 BIO-RAD LABORATORIES, INC. 168
TABLE 125 BIO-RAD LABORATORIES, INC: BUSINESS OVERVIEW 168
FIGURE 40 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2021) 169
12.1.8 THERMO FISHER SCIENTIFIC INC. 171
TABLE 126 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW 171
FIGURE 41 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2021) 172
12.1.9 DIASORIN 174
TABLE 127 DIASORIN: BUSINESS OVERVIEW 174
FIGURE 42 DIASORIN: COMPANY SNAPSHOT (2021) 175
12.1.10 PERKINELMER, INC. 177
TABLE 128 PERKINELMER INC: BUSINESS OVERVIEW 177
FIGURE 43 PERKINELMER INC: COMPANY SNAPSHOT (2021) 178
12.1.11 TOSOH CORPORATION 180
TABLE 129 TOSOH CORPORATION: BUSINESS OVERVIEW 180
FIGURE 44 TOSOH CORPORATION: COMPANY SNAPSHOT (2022) 181
12.1.12 LSI MEDIENCE CORPORATION (PHC HOLDINGS CORPORATION) 184
TABLE 130 LSI MEDIENCE CORPORATION: BUSINESS OVERVIEW 184
FIGURE 45 PHC HOLDINGS CORPORATION: COMPANY SNAPSHOT (2021) 184
12.1.13 QUIDEL CORPORATION 186
TABLE 131 QUIDEL CORPORATION: BUSINESS OVERVIEW 186
FIGURE 46 QUIDEL CORPORATION: COMPANY SNAPSHOT (2021) 186
12.1.14 RANDOX LABORATORIES 188
TABLE 132 RANDOX LABORATORIES: BUSINESS OVERVIEW 188
12.1.15 GUANGZHOU WONDFO BIOTECH CO., LTD. 190
TABLE 133 GUANGZHOU WONDFO BIOTECH CO., LTD.: BUSINESS OVERVIEW 190
12.1.16 BODITECH MED INC. 192
TABLE 134 BODITECH MED INC: BUSINESS OVERVIEW 192
12.1.17 TULIP (P) DIAGNOSTICS LTD 194
TABLE 135 TULIP (P) DIAGNOSTICS LTD: BUSINESS OVERVIEW 194
12.1.18 BTNX INC. 195
TABLE 136 BTNX INC.: BUSINESS OVERVIEW 195
12.1.19 RESPONSE BIOMEDICAL 196
TABLE 137 RESPONSE BIOMEDICAL: BUSINESS OVERVIEW 196
12.1.20 ALFA SCIENTIFIC DESIGNS, INC. 198
TABLE 138 ALFA SCIENTIFIC DESIGNS, INC: BUSINESS OVERVIEW 198
12.2 OTHER PLAYERS 199
12.2.1 CTK BIOTECH, INC. 199
12.2.2 CREATIVE DIAGNOSTICS 199
12.2.3 LIFESIGN LLC. 200
12.2.4 CARDIOGENICS HOLDINGS INC 200
12.2.5 ATLAS MEDICAL GMBH 201
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

13 APPENDIX 202
13.1 DISCUSSION GUIDE 202
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 206
13.3 CUSTOMIZATION OPTIONS 208
13.4 RELATED REPORTS 209
13.5 AUTHOR DETAILS 210


    お問合せフォーム

    • レポートのタイトルは自動で入ります。
    • *のある項目は必須項目です。

    お名前*

    会社名*

    部署名

    メールアドレス*

    電話番号

    当ウェブサイトを知った経緯を教えてください。

    お問合せ内容

    株式会社SEMABIZ・ChosaReport.com プライバシーポリシー

    Eメールでのお問合せもお受けしております。
    下記アドレスへ“(at)”を“@”に変えてお送りください。通常1営業日以内にご返信いたします。
    crinquiry(at)chosareport.com